MCMC
XBI icon

Matrix Capital Management Company’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Matrix Capital Management Company’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,100,000
Closed -$189M – 25
2022
Q1 		$189M Buy
+2,100,000
New +$194M 2.27% 16

Other funds holding XBI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Matrix Capital Management Company's XBI Position: Q2 2022 in Review

Matrix Capital Management Company sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 2,100,000 shares — an estimated $189M sold.

Matrix Capital Management Company first reported a position in XBI in Q1 2022 and held it in 1 quarter. The position peaked at $189M in Q1 2022. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

  • Matrix Capital Management Company reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
  • Matrix Capital Management Company sold 2,100,000 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $189M.
  • Matrix Capital Management Company first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 1 quarter.
  • Matrix Capital Management Company's State Street SPDR S&P Biotech ETF position peaked at $189M in Q1 2022.
  • 706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Matrix Capital Management Company's 13F filing for Q2 2022, filed 15 Aug 2022.